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Background: The high prevalence of HIV-associated comorbidities including neurocognitive disorder, high levels of
residual inflammatory mediators in the plasma and cerebrospinal fluid and the resurgence of HIV replication upon
interruption of antiviral treatment in HIV-1 infected individuals, strongly suggests that despite therapy HIV persists in
its cellular targets which include T-lymphocytes and cells of the myeloid lineage. These reservoirs present a major
barrier against eradication efforts. Knowledge of the molecular mechanisms used by HIV to modulate innate macrophage
immune responses and impair viral clearance is quite limited. To explore the role of HIV in potentially modulating
macrophage function through changes in protein expression, we used single-cell analyses with flow cytometry
to determine whether, in unpolarized cultures, macrophage surface marker phenotype was altered by HIV infection
in a manner that was independent of host genetic background.
Results: These analyses revealed that at several time points post-infection, GFP + HIV-infected macrophages were
significantly enriched in the CD14+ fraction (3 to 5-fold, p = .0001) compared to bystander, or uninfected cells in
the same culture. However, the enrichment and higher levels of CD14 on HIV expressing macrophages did not
depend on the production of HIV Nef. Sixty to eighty percent of macrophages productively infected with HIV
after day 28 post-infection were also enriched in the population of cells expressing the activation markers CD69
(2 to 4-fold, p < .0001) and CD86 (2 to 4-fold, p < .0001 ) but suppressed amounts of CD68 (3 to 10-fold, p < .0001)
compared to bystander cells. Interestingly, there was no enrichment of CD69 on the surface of HIV producing
cells that lacked Nef or expressed a variant of Nef mutated in its SH3-binding domain.
Conclusions: These findings suggest that HIV actively regulates the expression of a subset of surface molecules
involved in innate and inflammatory immune signaling in primary human macrophages through Nef-dependent
and Nef-independent mechanisms acting within productively infected cells.
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While in vivo evidence using macaque animal models
has supported the concept of the macrophage as a HIV
reservoir, similar studies in humans are hampered by
the need to use invasive means to extract tissue bound
macrophages from tissues and hence, far less is known
about the phenotype and turnover of these cells when
they are actively replicating HIV or harbor latently in-
fected viral genomes. Viral dynamics studies have sug-
gested that the second phase of HIV decay during
combination antiretroviral therapy (cART) is due to
the turnover of macrophages [1,2], but other studies
have disputed this notion [3]. The ability to purify and
quantify by cell sorting, and study the nature of la-
tently infected human macrophages would benefit from a
reliable donor-independent cell surface marker signature
that could distinguish these cells from productively in-
fected macrophages.
Bulk analyses of infected macrophages have been lim-
ited in their ability to discriminate whether changes in
surface marker expression occurred exclusively on the
productively infected cells, on the bystander uninfected
macrophages, or on both populations. Recombinant HIV
fluorescent reporter viruses have been in widespread use
although constructs that express all of the viral genes
and replicate in macrophages were developed later. There
is an urgent need to better understand in the cART era,
the molecular mechanisms of HIV-mediated immune acti-
vation as well as the role of macrophages as reservoirs. As
the productively infected cell is marked by a fluorescent
marker, HIV reporter viruses can be useful in this regard
in determining whether HIV acts directly and/or through
the induction of soluble factors to dysregulate macrophage
function. In this study, we used monocyte-derived human
macrophages (MDM) generated from normal donors dif-
fering in genetic background and susceptibility to HIV, in-
fected with recombinant macrophage-tropic GFP reporter
viruses to determine, in a longitudinal fashion, the surface
marker phenotype of the subpopulation of MDMs in
which the virus replicates. Additionally, the phenotype
of the bystander MDM, which are the uninfected cells
in the HIV exposed culture that do not express HIV,
and mock-infected cultures was also examined in par-
allel. We found that HIV-1 preferentially replicates in
MDM with an activated phenotype characterized by
the expression of CD14, CD69, CD86 and low levels
of CD68. Moreover, infection with HIV-GFP reporter
viruses that either lack Nef or expressed a mutated
form of Nef in its SH3-binding domain suggested that
Nef modulates the expression of CD69 on the surface
of infected macrophages. In contrast, the enrichment
of productively infected MDM expressing CD14 and
CD86 and suppressed levels of CD68 did not depend on
HIV Nef.Results
Characterization of monocyte populations isolated by
gradient density centrifugation
To ascertain whether the monocytes used in our studies
reflected the previously reported heterogeneity seen in
these cells, we performed flow cytometry for a panel of
known monocyte/macrophage cell surface molecules on
monocytes purified by density gradient centrifugation
from eight normal blood donors. First, to identify the
monocyte population, cells were costained with CD14.
The CD14+ population was identified as gate 1 against
side-scatter and then analyzed for the second marker
(Figure 1). As has been reported, the percentage of
monocytes in peripheral blood as well as the well-known
CD14/CD16 subpopulations can vary significantly be-
tween healthy donors. In the donors analyzed, the mono-
cyte fraction varied from 8.8-30% (Figure 1). The purity of
the CD14+ fraction after gating out any CD3+ cells was
92-99%. The percentage and intensity of monocytes ex-
pressing the Fc receptor CD16 varied with the donor
ranging from 7.3-24% of the CD14+ cells (Figure 1).
Differences in the level of CD16 as detected in the
mean fluorescent intensity (MFI) ranged from a low of
132 to a high of 652 and reflected the variation in the
number of CD14 + CD16lo and CD14+ CD16hi mono-
cytes among the donors, (Figure 1). While the HIV re-
ceptor CD4 and CCR5 coreceptor were detected at low
(0-2%) to moderate levels (13-26%), in contrast, integ-
rins CD11b and CD18 and the Fc receptor CD32 were
abundantly expressed (72-99%) on most donors (Figure 2).
The levels of Fc receptor CD64 varied markedly (0.28-
91%) depending on the donor monocytes (Figure 2). The
levels of CD33, a sialoadhesion expressed by monocytes
and macrophages and recently shown to be associated
with late-onset Alzheimer’s disease and the scavenger
receptor CD36 varied between donors (1-74%, CD33;
8-89%, CD36) (Figure 2). Lysosomal-associated mem-
brane protein-1 (LAMP-1 or CD107a), a lysosomal protein
found on the surface of activated monocytes [4] was
expressed at no or very low levels (0.2-4%) on most donors
except for one (10%) (Figure 2). Interestingly, the marker
for alternatively activated monocytes/macrophages, CD163
was detected at appreciable levels (16-73%) on most do-
nors, while in contrast CD206 levels were absent or min-
imal (0-.66%) (Figure 2). Out of the four donors analyzed
for this marker, CD169, a sialoadhesin implicated in
chronic HIV infection and disease progression [5–7]
was highly expressed on one donor (Do2291, 5%), but
at much lower levels on all other donors (1-2%) (Figure 2).
Toll-like receptor TLR2 (CD282) levels were variable ran-
ging from a low of 3-13% and high at 34-94% (Figure 2).
Levels of TLR3 (CD283) on the monocyte surface was low
on most donors (0.49-7%) and elevated on two other sam-

























17% 7.3% 24% 16% 
29% 8.8% 29% 30% 
Figure 1 Analysis of monocyte CD14/CD16 subpopulations in density gradient purified monocytes. Ficoll purified buffy coats from normal
blood donors were subjected to a second percoll gradient to enrich for monocytes and analyzed by flow cytometry for CD14/CD16
subpopulations. (Top row): The forward (FSC) and side scatter (SSC) of leukocytes after gradient purification and gating with the isotype controls
are shown. (Second row): The CD14 fraction of four different donors plotted against SSC is shown and the percentage of CD14+ monocytes is
given. (Bottom row): The CD14/CD16 population of four different donors is shown. The percentage of CD14 + CD16+ monocytes is given and the

















Figure 2 Variable expression of typical receptors on CD14+ monocytes from normal blood donors. Monocytes were double-labeled for
CD14 and the indicated markers and the percentage of positively labeled cells in the CD14+ fraction was quantified by flow cytometry. Two of
the donors, Do4787 (brown) and Do3528 (deep blue) were used in the longitudinal analyses of HIV-infected macrophages (Figure 3).
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monocytes (Figure 2). These data suggest that the density-
purified monocytes used in this study were characterized
by the abundance of known monocyte/macrophage
markers, which have been described for this popula-
tion and that the extent of expression of specific recep-
tors varied between normal donors.
Infection of monocyte-derived macrophages (MDM) with
the HIV-GFP reporter virus
The current state-of-the-art to study human macrophage-
HIV interaction is through the in vitro differentiation of
donor blood monocytes and infection with macrophage-
tropic viral isolates. Relatively few studies have character-
ized the human macrophage subsets that arise during
in vitro culture or investigated whether HIV-1 replicates
selectively in different populations. Two studies have re-
ported that HIV replication in macrophages polarized to
the M1- or M2-type was significantly reduced compared
to unpolarized conditions [8,9]. To determine the pheno-
type and frequency of M1- and M2-type macrophages in
our culture model and whether HIV had a preference to
replicate in a specific macrophage subpopulation, we in-
fected three different donor MDMs with the recombinant
macrophage-tropic HIVSF162R3Nef
+GFP reporter virus,
referred to as HIV-GFP [10,11]. The study design allowed
us to determine whether host genetic background had any
influence on macrophage surface phenotype as well as to
assess any impact on the subpopulation in which HIV
replicates. Moreover, we could analyze and quantify
the macrophages in which HIV actively replicated, via
GFP + single-cell analyses, as well as characterize the
bystander MDM, which do not express HIV, but are
present in the infected culture, something not possible
with previous studies using bulk culture methods. We
will refer to the mock-treated, HIV-GFP+, and by-
stander cells as “MDM groups”. The expression of GFP
indicates active transcription of the viral genome and
was followed by microscopy and quantified longitudin-
ally by flow cytometry. In infected cultures, both MDM
granularity and cell size increased with time in culture, a
phenomenon that is accelerated by HIV-mediated enhance-
ment of multinucleated giant cell formation (Figure 3). The
percentage and level of GFP expression in the live cell
population was quantified at 7–8 day intervals. Donor 4787
(Do4787) had a peak level of GFP +MDM of nearly 2%
(1.87 +/− 0.16%, n = 10) at day 14 post-infection (pi), while
Do3528 peaked at day 28 pi with about 7% GFP + (7.18 +/−
1.1%, n = 10), and Do9432 increased significantly (p < .0001,
n = 10) from D29 pi (10.84 +/− 1.2%) to peak at day 43 pi
at 23% GFP + (22.71 +/− 1.5%) (Figure 4). For Do3528 and
Do9432 viral spread as indicated by an increase in the
number of GFP +MDM with time, continued significantly
(p < .0001, n = 10) throughout the culture period in contrastto Do4787 where spread was more limited and occurred
up until day 21 pi (Figure 4). However, GFP mean fluores-
cent intensity (MFI) increased significantly (p < .0001,
n = 10) until day 21 pi for Do4787 (335 +/− 44.8) (Figure 4).
For Do3528 the GFP MFI increased significantly from day
7–14 pi (128 +/− 15.4 to 168 +/− 10.3) then dropped at
day 21 pi (146.5 +/− 14.5, n = 10) and did not vary much
for the remainder of the culture period (Figure 4). The GFP
MFI for Do9432 peaked at day 29 pi, (451 +/− 28, n = 10)
and then dropped significantly to 310 +/− 38.4 MFI and
remained near this level (Figure 4).
The variation in the extent of HIV replication among
these three donor MDMs reflected the genetic variation
in susceptibility to HIV that has been previously re-
ported [12]. To ascertain whether differences in recep-
tor expression were related to the extent of viral replication
seen among the donors, the levels of CD4 and CCR5 were
examined. Between donors, CD4 levels varied considerably
with Do4787 having high levels (40%) at early time points
that were rapidly lost with time, a low level of 4-10%, or very
minor expression of <1% with Donors 9432 and 3528, re-
spectively (Figure 4). In mock-treated MDM for Do9432,
CD4 levels remained detectable at a low level (9% or less)
throughout the culture period although the receptor was
downregulated on HIV-infected and bystander MDM
(Figure 4). It is known that HIV downregulates the ex-
pression of CD4 through interactions with its Env and
Nef proteins [13,14]. CCR5 expression also varied with
donor, but generally was typically 10% or less and
waned rapidly with time in culture (Figure 4), in agree-
ment with previous studies [15,16]. Compared to the
other two donors, Do4787 expressed relatively high
levels of CCR5 up to day 21 pi (38%), but was the least
susceptible to HIV replication and spread (Figure 4).
Hence, differences in the expression of CD4 and CCR5
between donor MDMs while likely contributing to the
initial infectivity [15–17], did not fully account for the
contrasts in the extent of replication observed. Two of
the donor monocytes used in the longitudinal analyses
had similar profiles of cell surface markers before dif-
ferentiation except for lower CD18 and CD282 and
higher CD283 levels on Do4787 compared to Do3528,
the donor with greater susceptibility to HIV infection
(Figures 1 and 2).
Longitudinal analyses of macrophage surface receptor
expression on mock-treated, HIV-GFP + and bystander
subpopulations
To determine whether HIV replication alters, in a donor-
independent way, the expression of macrophage subpopu-
lations as defined by the presence of known macrophage
surface markers, longitudinal analyses by flow cytometry
were performed. The culture conditions used in this study
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Figure 3 Longitudinal analyses of monocyte-derived macrophages (MDM) with HIV-GFP. Monocytes from three different donors,
Do4787, Do3528 and Do9432 were differentiated in RPMI 1640 complete medium without the addition of any exogenous cytokines. At day
7 post-differentiation, macrophages were infected with HIV-GFP and GFP fluorescence was quantified by flow cytometry at 7–8 day intervals.
The forward (FSC) and side scatter (SSC) and GFP + versus SSC, is shown in the panels. Fluorescent images of representative HIV-GFP infected
MDM cultures at the indicated time points are shown.
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macrophage differentiation. No exogenous factors were
added. Day 0 represented seven days after the differenti-
ation of monocytes into MDM and the time point at
which the cells were infected with HIV-GFP. Side and for-
ward scatter was used to gate out any dead cells. Macro-
phages in the live cell fraction (gate R1) were analyzed by
side scatter and in the FL1 channel (GFP) to identify the
infected (GFP+, gate R2) and bystander (GFP-, gate R3)
cells. The gated populations were then analyzed in the
FL2 (PE), FL3 (PerCP) or FL4 (APC) channels for the ap-
propriate antibody as shown in Figure 5.
Integrin receptor CD11b was expressed on 10% or less
on all MDM donors at day 0 (Figure 5). By day 7–14 pi,
the percentage of CD11b +MDM increased in all donors
over a wide range (5-55%), but the differences were not
significant. The peak in CD11b expression was thenfollowed by a precipitous decline, but remained detect-
able at a very low level on two of the three donors dur-
ing the entire culture period (Figure 5). Beta-2 integrin,
CD18, which can complex with CD11b forming the CR3
receptor, displayed a low level of expression of 5-20% on
all subpopulations at day 7 pi with no significant differ-
ences between groups (Figure 5). After day 7 pi, CD18
expression declined on all MDM groups (Figure 5).
The protein tyrosine phosphatase, CD45 was abundantly
expressed (50-100%) on all donor MDMs at day 0 and
remained high on all groups in all donors until day 28 pi
after which the receptor became undetectable on mock-
treated MDM, but remained elevated at 20-40% on HIV-
infected and bystander MDM in Do9432 (Figure 5). There
were no statistically significant differences between groups.
Next, the expression of the IgG receptors, which are




































































Figure 4 Quantification of GFP +HIV-infected macrophages and HIV receptor and coreceptor expression. (A) The percentage and mean
fluorescent intensity (MFI) of GFP +macrophages for each donor (Do4787, Do3528 and Do9432) at the indicated time points after infection as
quantified by flow cytometry is shown (mean and standard deviation). (B) The percentage of the macrophages expressing the HIV receptor CD4
and coreceptor CCR5 was determined at the indicated time points. ***p < .0001.
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CD16 (FcγR1) varied from 18-38% depending on the
donor (Figure 5). CD16+ levels increased to 30-50% after
day 7 pi on all MDM groups until day 14 pi before grad-
ually decreasing (Figure 5). There were no significant dif-
ferences in CD16+ levels between MDM groups (Figure 5).
The FcγRII, CD32, which mediates phagocytosis and
oxidative burst, increased in expression from day 0 to
day 7 from 20% up to as much as 80% on some donors
and remained at high levels on all donors and subpopu-
lations throughout the culture period (Figure 5). There
were no significant differences in CD32 levels between
MDM groups during the culture period. CD64 expres-
sion was low at less than 10% at day 0 on all donor
MDMs and was depending on the donor, upregulated
thereafter particularly on HIV + and bystander MDM
however, the differences between groups were not sig-
nificant. The rapid decrease in CD64 levels seen with
time after day 14 pi for some donors did not appear to
be associated with HIV infection as the same kinetics
were observed on mock-treated MDM (Figure 5).
CD36, the collagen type I or thrombospondin receptor
was, depending on the donor, expressed at moderate levels
of 20-70% between day 0–7 pi and then was rapidlydownregulated on all MDM groups, but no significant dif-
ferences between groups were detected (Figure 5). The man-
nose receptor, a marker of M2-type- or alternatively
activated macrophages, CD206 was upregulated on all
MDM groups after day 7 pi reaching levels as high as
23% in some cases, but there were no significant differ-
ences between groups (Figure 5). At day 14 pi, in the
HIV-infected and bystander groups and day 28 in the
mock-infected group, CD206 levels fell rapidly thereafter.
Another marker of alternatively activated macrophages,
CD163 was largely absent at day 0 on all MDM groups
despite being present on their respective monocytes at
levels of 45-50% (Figures 5 and 2). An increase in CD163
expression of 2-8% was first detected at day 7 pi in the
HIV-infected and bystander MDM groups (Figure 5). At
day 14 pi levels increased to 8-18% on all MDM groups
and the differences were not significant. Thereafter,
CD163 expression declined to undetectable on all sub-
populations and was not quantified at later time points
(Figure 5). Other M2-type receptors such as CD209,
CD360 (IL-21R), and M1-type surface molecules such
as CD127, CD215 and HLA-DR were either not de-
tected or seen at negligible levels in this MDM culture
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Figures 5 Longitudinal analyses of surface marker expression in mock, HIV-GFP infected and bystander macrophages. Mock- and
HIV-GFP infected macrophages were harvested at 7–8 day intervals and stained for flow cytometry for the indicated markers. The day 0 time
point is given only for the Mock sample and represents the day of infection. The uninfected or GFP negative cells in the HIV-GFP culture
were designated as the bystander MDM (BYSTD). For each group the combined mean percentage of positively stained cells and standard
deviations from all three donors is shown. Statistical comparisons were determined by one-way ANOVA with Tukey’s test for multiple comparisons
and significance of p < .05. For the receptors shown, no significant differences were found. For the day 43 pi time point, values shown are from a single
donor, Do9432.
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macrophages
In contrast to the macrophage markers analyzed above,
a different pattern was observed for CD14, CD69, CD86
and CD68. Representative scatter plots are shown in
Figure 6. The percentage of CD14+ macrophages at
day 0 to day 14 in culture varied with donor but gener-
ally started out low at 0.1-6% and then dramatically in-
creased up to 80% on some MDM groups (Figure 7).
At day 14 pi the difference in CD14 levels betweenHIV-infected (63.8 +/− 18.3, n = 17) and bystander
MDM (47.3 +/− 27.9, n = 18) (p = .047) approached
significance (Figure 7). After day 21 pi, the level of
CD14+ on HIV-infected MDM (46.5 +/− 15.1, n = 16;
day 28; 41.7+/−13.3, n = 12) significantly exceeded the
levels on bystander cells (21.8 +/− 6.71, n = 16 day 28;
16.5 +/−5.62, n = 11; day 35; p = 1.4e-6, day 28; p = 9.2e-6,
day 35) (Figure 7). CD14+ macrophages were significantly
greater in the HIV-infected group (63.8 +/− 18.3, n = 17,
day 14; 41.7 +/−13.3, n = 12, day 35) compared to
Figure 6 Flow cytometric analyses for CD14, CD69, CD86 and CD68 expression on the surface of HIV-GFP infected MDM. Representative
scatter plots are show for the MDM donor data summarized in Figure 7. Left column. Forward (FSC) and side scatter (SSC) for mock-infected and
HV-GFP gated for the live cells (R1) is shown and the percentage of live cells indicated. Second column from left. MDM in the live cell gate (R1)
were analyzed by SSC and in the FL1 channel to identify the GFP + HIV-infected MDM (gate R2) and the GFP- or bystander cells (gate R3).
Mock-infected MDM stained with isotype control antibodies were used for gating as indicated in the top row. The cells in gates R2 and R3
were then analyzed in the FL4 channel for the indicated surface markers. The percentage of positive cells and the mean fluorescent intensity
of staining are given.
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8.67, n = 10, day 35) at Day 14 and 35 pi (p = .0007, D14;
p = 3e-6, D35, n = 7), but lower in Do9432 at D43 pi
(mock: 22.8 +/− 8, HIV: 5 +/− 2.13, p = .0009, n = 6)
(Figure 7).
In all three donors there was no or low-level expression
(3.5%) of CD69 at day 0 (Figure 7). However, by day 28 and
35 pi, CD69 expression was significantly higher on HIV-
GFP +MDM (60.4+/−8.87, n = 6, day 28; 54.8 +/−11.6,
n = 4, day 35) compared to bystander cells (23.11 +/−
20.5, n = 6, day 28; 27.6 +/− 5.6, n = 4; day 35; p = .002,
day 28; p = 0.005, day 35) (Figures 6 and 7). Abundantexpression of CD69 was maintained on HIV-GFP +
MDM for all donors at all subsequent time points (mean
std, p = .0002, n = 3, day 28 pi; mean std, p = .005, n = 3,
day 43 pi). With Do9432, in contrast to the other two do-
nors, CD69 expression was also high on mock-treated
MDM suggesting that this donor possessed an intrinsic
high level of activation (Figure 7).
The costimulatory marker CD86 was by day 14 pi sig-
nificantly induced on HIV-GFP +MDM (45.8 +/− 6.56,
n = 5) compared to mock-treated cells (4.92 +/− 0.39,
n = 3, p = 4.5e-5) and was sustained at day 28 (mock:
22 +/− 28.5, HIV: 46.7+/− 9.95, p = .026, n = 9) and day 35





















































Figure 7 Surface markers expression on mock, HIV-GFP + or bystander macrophages from Do4787, Do3528 and Do9432. Mock- and
HIV-GFP infected macrophages were harvested at 7–8 day intervals and stained for flow cytometry for CD14, CD68, CD69, and CD86. The day 0
time point is given only for the Mock sample and represents the day of infection. The uninfected or GFP negative cells in the HIV-GFP culture
were designated as the bystander MDM (BYSTD). For each group the combined mean percentage of positively stained cells and standard deviations
from all three donors is shown. Statistical comparisons were determined by one-way ANOVA with Tukey’s test for multiple comparisons and
significance of p < .05.
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(Figure 7). CD86 levels were significantly higher on HIV-
GFP +MDM compared to bystander MDM beginning at
day 35 pi (HIV: 67.7+/− 5.89, Bystander: 33.5 +/− 19.4,
n = 4) and a similar trend was observed in Do9432 at
day 43 pi HIV: 65.2 +/− 2.92, Bystander: 34.1 +/− 1.77,
n = 2) (Figures 6 and 7).
Expression of CD68, a member of the scavenger recep-
tor family was variable depending on the donor and
ranged from a low of 3% to a high of 66% on mock-
treated and bystander MDM on all donors from day 7
up to day 35 pi, however the differences were not signifi-
cant (Figure 7). Compared to levels on bystander MDM
at day 28 pi, CD68 was significantly downregulated on
HIV-GFP +MDM (HIV: 7.74 +/− 6.98, p = .01, n = 4;
mock: 37.7+/− 28.9, n = 4), and remained low on HIV-
infected MDM at all time points (Figure 7).
Based on analyses of the mean fluorescent intensity
(MFI) for CD14, significantly higher density of this re-
ceptor was detected on HIV-GFP +MDM compared tobystander cells at day 14 after infection (Table 1). Simi-
larly, the density of CD86 on HIV-GFP +MDM exceeded
that on bystander cells at day 21–28 post-infection
(Table 1). No other significant differences in MFI be-
tween the HIV-GFP + and bystander groups were seen
at other time points or with CD69 or CD68. These
findings suggest that, irrespective of their overall dens-
ity on the surface, CD14, CD69, CD86 and CD68low
represent a potential consensus surface marker pheno-
type of productively HIV-infected macrophages.
Active modulation of macrophage surface phenotype by
HIV Nef-dependent and independent mechanisms
Our results suggested that CD14, CD68, CD69 and
CD86 cell surface expression is altered in macrophages
that are actively replicating HIV and not on the by-
stander uninfected cells. Alternatively, it was possible
that MDM expressing the appropriate levels these recep-
tors were the preferred target cells of HIV and that there
was no active modulation by infection. To distinguish
Table 1 Comparison of marker mean fluorescent intensity on Do4787, Do3528, and Do9432 macrophages
Marker CD14 CD69 CD86 CD68
Sample Mock HIV-GFP+ Bystander Mock HIV-GFP+ Bystander Mock HIV-GFP+ Bystander Mock HIV-GFP+ Bystander
Day 0 Avg 39.12
(n = 8)
n/a n/a 48.21 n/a n/a 68.57 n/a n/a 68.66 n/a n/a




Day 7 Avg 59.81
(n = 9)
39.15 32.28 54.49 44.38 29.24 53.85
(n = 4)
30.59 43.45 47.69 20.95 16.22










49.99 34.05 71.86 67.91 53.59










74.33 33.49 97.86 128.51 96.52










86.41 60.91 62.45 100.37 66.34
Day 29–35 SD 23.99 24.43 12.39 19.88 16.75 12.28 57.61 34.87 7.52 36.22 82.29 12.36
Significance
p < .05
Data were analyzed in unpaired t tests with Holm-Sidak correction for multiple comparisons and significance at p < .05 using GraphPad Prism 6 software.
Significant differences between the HIV-GFP+ and bystander groups are indicated in bold and by an asterisk.
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with the initial three donors, we used nine different
donor MDMs infected with HIV-GFP, with a variant
lacking Nef, or expressing a mutant form of Nef inacti-
vated in the SH3-binding domain [10,18]. Nef, which is
required for pathogenesis in vivo and for high-level rep-
lication in primary cells [19–22], has been shown to
downregulate a number of cell surface molecules im-
portant for immune surveillance and antigen presenta-
tion [13,14,23,24]. MDM were harvested at day 15 or
day 21–28 pi and stained with fluorescently labeled anti-
bodies against CD14, CD69, CD86 and CD68 and ana-
lyzed by flow cytometry. Representative scatter plots for
each of these markers are shown in Figure 8A-D. The
round, fried-egg appearing macrophages were the pre-
dominant morphology seen in the majority of these cul-
tures, however four of the nine donors shown had
significant numbers of spindle-shaped macrophages
(Figure 9 B, D, G and H). Despite this heterogeneity, a
significantly higher percentage of HIV-Nef + infected
MDMs (HIV-GFP) expressed CD14 compared to mock-
infected (p = .0001) and HIV-bystander MDMs (mock:29.4 +/−13.3; HIV-GFP Nef+: 64.6 +/− 19.1, HIV-Nef +
Bystander: 19.5 +/− 10.5, p < .0001, n = 9, Figures 8A and
9). There was a trend of a higher number of CD14+
MDM infected with the Nef- mutant compared to the
Nef-Bystander cells (Nef-: 44.2 +/− 17.4, Nef-Bystander:
17.7+/− 6.5, p = .057, n = 5), while a significant difference
in the percentage of CD14+ macrophages productively
infected with the Nef P7480 variant compared to its
bystander population was detected (Nef P7480: 49.8 +/−
13.7, Nef P7480-Bystander: 18.8+/− 9.5, p = .015, n = 5,
Figures 8A and 9). These results suggested that Nef is not
required for the enrichment of CD14 on productively in-
fected MDM.
The percentage of MDM expressing CD69 was signifi-
cantly higher on HIV-GFP Nef +MDM compared to
mock and HIV-Nef + bystander cells (mock: 39.6 +/−
18.9, p = .022, n = 17; HIV: 61.7 +/− 25.5; HIV-Nef +
Bystander: 26.4 +/− 17.8, p < .0001, n = 17, Figures 8B
and 9). In contrast, CD69 surface expression was not dif-
ferentially enriched on MDM infected with the Nef-
or Nef P7480 mutants compared to their respective








































































































































Figure 8 Flow cytometric analyses for CD14, CD69, CD86 and CD68 expression on the surface of MDM infected with the HIV-Nef+,
HIV-Nef- and HIV-NefP7480 GFP reporter viruses. Representative scatter plots are show for the MDM donor data summarized in Figure 9. For
each panel A-D: Top row: mock-infected MDM stained with isotype controls or CD14-APC antisera. Left column. Forward (FSC) and side scatter
(SSC) for the indicated infected MDM gated for the live cells (R1) is shown and the percentage of live cells indicated. Second column from left. MDM in
the live cell gate (R1) were analyzed by SSC and in the FL1 channel to identify the GFP + HIV-infected MDM (gate R2) and the GFP- or bystander cells
(gate R3). The percentage of GFP + cells is indicated in the lower right corner and of bystander cells in the upper left as indicated by the arrow. Third
and fourth columns from left. The cells in gates R2 and R3 were then analyzed in the FL4 channel for CD14 (Figure 8A), CD69 (Figure 8B), CD86 Figure 8C
and CD68 (Figure 8D). The percentage of positive cells and the mean fluorescent intensity of staining are given.
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http://www.retrovirology.com/content/10/1/15529.2 +/− 21.4, n = 12; Nef P7480: 48 +/− 18.2, Nef
P7480-Bystander: 21.9 +/− 18, n = 6) (Figures 8B and 9).
These data suggest that a functional Nef protein with an
intact SH3-binding domain expressed in the productively
infected macrophage is required for the enrichment of
CD69 on the cell surface.
An increased percentage of CD86+ MDM in the HIV-
GFP Nef + compared to mock and HIV-Nef + bystander
MDM was confirmed on the larger donor set (mock:
31.8 +/− 13.1; HIV: 51.4+/− 18.6; HIV-Bystander: 25.48 +/−
14.58; Nef-: 57.3 +/− 12.9; Nef-Bystander: 25.9 +/− 13.8; Nef
P7480: 48.5 +/− 19.6; Nef P7480-Bystander: 16.5 +/− 9.7;p < .0001, n = 20 Figures 8C and 9). Significantly enrichment
of CD86 was also found on MDM infected with the Nef-
and Nef P7480 variants compared to their respective by-
stander cells, suggesting that Nef is not required for
the upregulation of this receptor (Figures 8C and 9).
Strong suppression of CD68 levels were seen on
MDM infected with HIV-GFP Nef+, Nef- and the Nef
P7480 variants compared to their respective bystander
MDM and mock-treated cells (mock: 28.2 +/− 11.7; HIV:
5.75 +/− 3.64; HIV-Bystander: 25 +/− 4.6, n = 13; Nef-
8.64 +/− 5.8; Nef-Bystander 35.1 +/− 11.5, n = 6; Nef
P7480 5.11 +/− 2.61; Nef P7480-Bystander, 29.4 +/− 8.77;
A B
C D























































Figure 9 HIV Nef-dependent and Nef-independent modulation of HIV-GFP macrophage cell surface phenotype. Nine donor MDM
infected with HIV-GFP, HIV-GFP-Nef-, HIV-GFP-Nef P7480, or mock-treated were harvested between day 15–28 post-infection and analyzed by flow
cytometry with anti-CD14-PE and CD69-APC or CD68-PE and CD86-APC as shown in the panels at the upper left. Statistical comparisons were
determined by one-way ANOVA with Tukey’s test for multiple comparisons and significance of p < .05, *** < .0001. Images of macrophage
monolayers of nine donors at day 15 pi is shown. Figure 9A-I.
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that Nef does not play a role in modulating the surface
levels of this receptor and hence, additional HIV-mediated
mechanisms in productively infected macrophages are in-
volved in the suppression of CD68 expression.
Discussion
Macrophages are exquisitely sensitive to their micro-
environment having the ability to respond to innate im-
mune signals and modify their gene expression profiles
[18]. In this study exogenous cytokines were not used to
polarize macrophages to the M1- or M2-type subpopula-
tions that have been descried [8]. Instead, we wanted to
determine whether HIV infection could promote macro-
phage gene expression changes along M1-, M2- or some
other type of pathway. While the majority of donor mac-
rophages upon differentiation exhibited a round morph-
ology with a fried-egg appearance, 80% of donors alsocontained significant numbers of spindle-shaped cells.
This is of note as it has been reported that monocytes
differentiated under non-polarized conditions exhibit a
round morphology and possess M2-like characteristics
such as CD163 and TGF-β2 expression while spindle-
shaped macrophages had a pro-inflammatory profile
[25]. The majority of the macrophages in the herein de-
scribed cultures had a round morphology and did not
express CD163, highlighting variation that is observed in
different culture models. The expression of M2-type re-
ceptors CD163 and CD206 was very low in our culture
model in agreement with a study by Porcheray et al.
[26]. Lacking the ability to quantify receptor levels separ-
ately on infected and bystander macrophages, the latter
study reported that CD14 levels were dramatically de-
creased on all macrophages in HIV-infected cultures
with time [26]. CD86, which was highly expressed on
HIV-infected macrophages, and other receptors including
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as markers for M1-type macrophages [18,27], but were ab-
sent from HIV-GFP infected cells. The HIV-infected mac-
rophages in our culture model appear to be most related
to the M1-type by the presence of CD86 and the height-
ened state of activation indicated by the enrichment of
CD69 and CD14 on the cell surface but are clearly differ-
ent from the prototypical M1-type macrophages. More-
over, our study revealed for the first time that changes in
gene expression within the productively infected macro-
phage that impact CD14, CD69, CD86 and CD68 levels
do not impact cells in the same culture, which are not ex-
pressing HIV. This suggests that alterations in the level of
the latter surface molecules are not impacted by the re-
lease of soluble factors.
Indeed, the ability to analyze the cell surface of pro-
ductively HIV-infected macrophages as well as the GFP
negative, uninfected cells in the same culture allowed us
to determine that HIV viral proteins play an active role
in modulating the surface phenotype of these cells irre-
spective of differences in genetic background and suscep-
tibility to HIV replication between donor macrophages. A
consensus cell surface signature on macrophages that ac-
tively express HIV defined as CD14+, CD69+, CD86+ and
CD68low was found to be consistent on the 12 different
donors used in this study. This signature is expected to be
present on MDM when HIV replication is robust and to
wane as viral expression decreases. CD69 was significantly
increased on HIV-infected cells only when Nef was pro-
duced. Expression of Nef encoding mutations within its
SH3-binding domain did not restore elevated levels of
CD69 on infected macrophages, implicating this protein
interaction domain in the mechanism of CD69 upregula-
tion. An activated cellular microenvironment as found in
cells at the G1b to G1/s boundaries allows for efficient HIV
replication as the host cell factors involved in promoting
reverse transcription, nuclear import and transcription are
more highly expressed under these conditions [28,29].
Additionally, HIV has evolved mechanisms to infect non-
dividing cells like macrophages. In this regard, Nef protein
is required for high-level replication of HIV in primary
macrophages and T-cells [20,22,30], for pathogenesis in
several animal models of HIV infection [31,32] and in
humans infected with variants lacking Nef, the disease
course is very attenuated [33]. HIV Nef downregulation of
CD4 [34] and selective classes of MHC class I molecules
[23] from the surface of infected cells in a mechanism,
which facilitates immune escape from CTL lysis [35] while
providing protection from NK cell lysis, has been well
characterized in the context of viral infection or primary
HIV target cells and in a variety of culture models and
over-expression systems. The PXXP or SH3-binding do-
main of Nef is required for the downregulation of MHC
class I, but not CD4 [36,37] and is under strong immuneselection in vivo being highly conserved in patient derived
Nefs [38]. Less well characterized is Nef ’s ability to upreg-
ulate CD74, and DC-SIGN, and downregulate CD206,
CD1, CCR5, CD71, CD80/CD86 and CD8 [39]. In this
study with single-cell analyses, we were able to analyze the
surface phenotype of HIV-infected and bystander unin-
fected macrophages and found that in contrast to earlier
reports [40,41] that CD86 while present at low levels on
bystander cells, is in fact increased 2 to 4-fold on HIV-
infected macrophages. As bystander cells in this study out-
numbered HIV-infected macrophages from as high as
50:1 to 5:1, this phenotype could not be observed without
a method to specifically quantify productively infected
cells. We found that donors differed in their level of basal
expression of CD86 and CD69. Do9432, which showed
the highest susceptibility to HIV replication, expressed
high levels of CD86 and CD69 in the absence of infection.
Indeed, a correlation between CD86 levels on macro-
phages and HIV replication was previously reported [42].
In most HIV-infected individuals on anti-viral therapy,
undetectable levels of HIV in the plasma suggest that
viral replication is effectively suppressed. However, inflam-
matory mediators including sCD14, IL-6, IL-8, CCL2,
CCL3, CXCL10, IFNγ remain readily detectable and ele-
vated compared to uninfected individuals [43,44]. Discon-
tinuation of anti-viral drugs results in the resurgence of
HIV replication in a little as a few weeks [45] and this
finding together with the persistent immune activation,
confirms that cellular and tissue reservoirs remain active.
Much is known about the nature of the resting CD4+
T-cell reservoir, but the same is not true of tissue mac-
rophages. In addition, much remains to be learned
about HIV-infected macrophages and their role in the
innate response and engagement and activation of T-cells.
CD69 is a member of the NK cell gene complex family of
signal transducers and an early T-cell activation marker as
its presence on T-cells is followed by CD25 and at later
stages of activation by MHC class II, HLA-DR. However,
comparatively little is known with regard to CD69 func-
tion on human macrophages. IFN-γ with LPS or TNF-γ
can increase CD69 expression on murine macrophages
and engagement of the receptor on monocytes results in
the induction of calcium flux, nitric oxide and cytosolic
PLA2 activation [46]. The ligand for CD69 remains un-
known. Recent studies in CD69-KO mice suggest a non-
redundant role of the receptor in the downregulation of
immune responses through TGF-γ [47]. Blocking CD69
impairs oral tolerance, exacerbates arthritis as well as
other autoimmune disorders by blocking the differenti-
ation of Th17 lymphocytes [47]. Monocytes with in-
creased expression of CD14 and CD69 have been
reported in HIV-associated dementia and culture su-
pernatants from the latter were shown to induce apop-
tosis in human brain aggregates [48]. More recently
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role in acute lung injury [49]. In acute lung injury, as
well as in mice studies of intracellular bacterial infec-
tion, the evidence points to a role for CD69 as a nega-
tive regulator of immune activation [49–51].
CD14 is a high-affinity GPI-linked receptor for LPS
and together with TLR4 helps to activate monocytes and
stimulate cytokine secretion from these cells. Recent stud-
ies have shown that CD14 is required for TLR4 transport
to endosomes [52]. TLR4 levels were very low or un-
detectable on MDM at multiple time points. In agreement
with this, recent microarray analyses by Brown et al., re-
ported that HIV stimulates a M1-type gene transcription
program in macrophages independently of TLR activation
[53]. A better understanding of the regulation of CD14
signaling on HIV-infected macrophages is needed to de-
termine how this pathogen modulates innate and adaptive
host immune responses.
The central costimulatory molecule B7.2 or CD86 is
mainly expressed on antigen presenting cells and plays a
role, through ligation to ligand CD28 or CLTA-4, acti-
vates or suppresses immune responses respectively, on
naïve or memory T-cells. CD86 was reported to be in-
creased on T-cells in HIV infection [54,55] and Wang
and Lewis showed, in agreement with our results, that
HIV production correlated with CD86 expression on
macrophages [42]. In this regard, signal transduction via
CD86 can lead to the activation of NFγ-γ, which is a
well-known enhancer of HIV replication. Other intracel-
lular pathogens like Toxoplasmosis gondii show increased
expression of CD86 on murine macrophages [56]. Inter-
estingly, choroid plexus and perivascular macrophages in
the brain express costimulatory molecules that are likely
increased upon the entry of pathogens into the brain and
under conditions of injury and/or neurodegeneration [57].
Conclusions
Our findings suggest that monocyte-derived macro-
phages productively infected with HIV express CD14,
CD69, CD86 and low levels of CD68 on their cell sur-
face. The enrichment of HIV in this subpopulation of
macrophages utilizes mechanisms that are independent
of HIV Nef in the case of CD14, CD86 and CD68, but
require Nef function to modulate CD69 surface expres-
sion. Interestingly, for the consensus surface markers
identified, the release of potential soluble factors by
HIV-infected macrophages does not appear to alter the
surface phenotype of bystander cells. These findings il-
lustrate how viral infection can influence host cell gene
expression most likely for the purpose of usurping in-
flammatory signaling pathways that could potentially
inhibit HIV replication. Uncovering the macrophage-
ligand-receptor interactions and functions of the con-
sensus signature at the molecular level is needed tobetter understand HIV modulation of innate immunity
and the nature of viral persistence in macrophages.
Methods
Monocyte isolation, differentiation and culture
Leukopaks from healthy donors were obtained from the
New York Blood Center in accordance with a study
protocol NA_00030244 approved by the Johns Hopkins
Institutional Review Board. The buffy coat was isolated
by Ficoll-Paque density gradient centrifugation. Mono-
cytes were subsequently enriched using a 46% percoll
density gradient [58]. Monocytes were cryopreserved in
RPMI1640/20% FBS/10% DMSO until further use. Ap-
proximately 1–3 x106 monocytes were differentiated in
T-25 flasks treated with CellBind (Corning) in RPMI1640/
20% FBS/10% human AB sera/1% penicillin-streptomycin,
1% glutamax and 1 sodium pyruvate (Invitrogen) for two-
three days and then switched to the same medium without
human sera (RPMI1640 complete medium). No exogen-
ous cytokines were added, but both the FBS and human
sera were tested empirically for their ability to support ef-
ficient monocyte differentiation.
Infection of human monocyte-derived macrophages with
HIV reporter viruses
At seven days post-differentiation human monocyte-derived
macrophages (MDM) were infected with HIVSF162R3
Nef + (HIV-GFP), HIVSF162R3 Nef- (HIV-GFP-Nef-), or
HIVSF162R3 Nef-P7480 in RPMI1640/2%FBS overnight
[10]. The next day the medium was removed and re-
placed with RPMI1640 complete medium. For the first
two weeks the entire culture supernatant was changed
every 3–4 days and thereafter, about once a week. At
the indicated time point medium was removed, MDM
rinsed with PBS before the addition of 1–2 ml of Accu-
tase (Chemicon or Sigma) to detach the cells. MDM
were incubated in Accutase at 37°C for 30 min-1 hr.
MDM were collected and washed in PBS/2%FBS/
5 mM EDTA/10 mM sodium azide for immunostaining
for flow cytometry.
Flow cytometric methods and data analyses
The fluorescently conjugated antibodies and isotype con-
trols (IgG1 clone MOPC-21, BioLegend) were used in
single or 3-color combinations: CD4 (clone OKT4, Bio-
Legend), CD11b (clone ICRF44, BioLegend), CD14 (clone,
TuK4, Invitrogen), CD16 (clone 3G8, Invitrogen), CD18
(clone 6.7, eBioscience), CD32 (clone FUN-2, BioLegend),
CD33 (clone WM53, BioLegend), CD36 (clone CB38; BD
Biosciences Pharmigen), CD64 (clone, 10.1, BD Biosci-
ences Pharmigen), CD68 (clone eBioY1/82A, eBioscience),
CD69 (clone CH/4, Invitrogen), CD86 (clone BU63, Invi-
trogen), CD127 (clone A019D5, BioLegend), CD163 (clone
GHI/61, BioLegend), CD195 (clone 45549, R&D Systems),
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(clone eB-h209, eBioscience), CD282 (clone TL2.1, BioLe-
gend), CD283 (clone TLR3.7, eBioscience), CD284
(clone HTA125, eBioscience), CD289 (clone eB72-1665,
eBioscience), and CD360 (clone 2G1-K12, BioLegend).
Stained cells were analyzed on a FACSCalibur using Cell-
Quest software (BD Biosciences). For the time course
studies, all three donors were harvested, stained and ana-
lyzed on the same day. The population of cells enriched
for monocytes after ficoll/percoll density gradient centri-
fugation were identified through CD14 vs side scatter. The
CD14 gate excluded any T-cell contamination as deter-
mined by anti-CD3 co-staining. Monocytes in the CD14
gate were then quantified for the second marker. For
MDM, live cells were defined using forward and side scat-
ter properties and designated in gate 1 (R1). MDM in the
R1 gate were then plotted against side scatter and FL1 for
GFP expression (gate 2, R2) or for the bystander cells (gate
3, R3, GFP negative). For HIV-GFP infected cultures, gates
delineating the GFP + and bystander MDM were gener-
ated and analyzed separately for the expression of the in-
dicated cell surface markers.
Data analyses
Statistical analyses were performed using GraphPad Prism
6 to determine mean, standard deviations, and significance
using multiple unpaired t-tests or one-way ANOVA. Sig-
nificance was determined by p values less than 0.05 and
corrected with Tukey’s test for multiple comparisons.
Microscopy
Images of MDM monolayers were captured at the indi-
cated time point using a Nikon E2000U inverted epi-
fluorescence microscope or Zeiss Axiovert A1 inverted
microscope. Images were processed with Adobe Photo-
shop and included adjusting the color balance, contrast
and application of the unsharp mask filter.
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